Table 4.
Summary of non-surgical adverse events
| Adverse events | CA-SAP group (n = 51) | SAP group (n = 53) | ||
|---|---|---|---|---|
| Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |
| Hematologic | ||||
| Neutropenia | 21 (41.2) | 5 (9.8) | 27 (50.9) | 3 (5.7) |
| Leukopenia | 30 (58.9) | 7 (13.7) | 35 (66.0) | 4 (7.5) |
| Thrombocytopenia | 7 (13.7) | 1 (2.0) | 0 (0.0) | 2 (3.8) |
| Anemia | 15 (29.4) | 1 (2.0) | 21 (39.6) | 0 (0.0) |
| Gastrointestinal | ||||
| Nausea | 19 (37.3) | 0 (0.0) | 23 (43.4) | 0 (0.0) |
| Vomiting | 11 (21.6) | 0 (0.0) | 13 (24.5) | 0 (0.0) |
| Anorexia | 10 (19.6) | 0 (0.0) | 11 (20.8) | 1 (1.9) |
| Diarrhea | 14 (27.5) | 2 (3.9) | 8 (15.1) | 2 (3.8) |
| Bleeding | 8 (15.7) | 1 (2.0) | 8 (15.1) | 1 (1.9) |
| Liver | ||||
| AST elevation | 11 (21.6) | 3 (5.9) | 8 (15.1) | 3 (5.7) |
| ALT elevation | 9 (17.6) | 5 (9.8) | 10 (18.9) | 3 (5.7) |
| Bilirubin increased | 8 (15.7) | 0 (0.0) | 8 (15.1) | 0 (0.0) |
| Cardio-renal | ||||
| Hypertension | 10 (19.6) | 0 (0.0) | 2 (3.8) | 0 (0.0) |
| Proteinuria | 8 (15.7) | 0 (0.0) | 1 (1.9) | 0 (0.0) |
| Respiratory | ||||
| Immune pneumonitis | 2 (3.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Dermatologic | ||||
| Rash | 9 (17.6) | 0 (0.0) | 5 (9.4) | 0 (0.0) |
| Hand–foot syndrome | 8 (15.7) | 0 (0.0) | 1 (1.9) | 0 (0.0) |
| Systemic | ||||
| Fatigue | 15 (29.4) | 1 (2.0) | 19 (35.8) | 1 (1.9) |
| Fever | 10 (19.6) | 0 (0.0) | 5 (9.4) | 0 (0.0) |
| Others | ||||
| Peripheral sensory neuropathy | 6 (11.8) | 0 (0.0) | 7 (13.2) | 1 (1.9) |
| Hypothyroidism | 7 (13.7) | 0 (0.0) | 1 (1.9) | 0 (0.0) |
| Stomatitis | 9 (17.6) | 1 (2.0) | 4 (7.5) | 0 (0.0) |
Data are No. (%).
CA-SAP camrelizumab, apatinib, nab-paclitaxel, and S-1, SAP nab-paclitaxel and S-1.